Macromolecular Biomaterials Endowed Strategies for Synergistic Treatment of Psoriasis: Recent Advancements and Future Prospects

Abstract

Psoriasis is a chronic autoimmune skin disorder that affects millions of individuals worldwide, causing discomfort and significantly impacting their quality of life. Recent advancements in the field of biomaterials and drug delivery have opened up promising avenues for the treatment of psoriasis. This manuscript summarizes key developments in the use of biomaterials and innovative drug delivery strategies to enhance the management of psoriasis. Biomaterials offer a versatile platform for the localized and sustained delivery of therapeutic agents to psoriatic lesions. Biocompatible materials, such as hydrogels and nanoparticles, have been engineered to encapsulate drugs and biologics, providing controlled release kinetics that maximize drug efficacy while minimizing systemic side effects. These biomaterial-based delivery systems have demonstrated remarkable potential in targeting the pathological mechanisms underlying psoriasis, including inflammation, hyperproliferation of keratinocytes and abnormal immune responses. In addition, recent advancements in personalized medicine have allowed for the tailoring of drug formulations to individual patient needs, optimizing treatment outcomes. Emerging technologies, such as 3D bioprinting, enable the creation of patient-specific skin models for drug screening, promoting the development of precision therapies. Future prospects in this field include the integration of smart biomaterials that respond to disease-specific cues, enabling on-demand drug release and real-time monitoring of therapeutic responses.